Loading
Life sciences · Journal article
Visual Computing for Industry Biomedicine and Art · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Prognosis prediction is important for precision treatment in lung cancer. Chest computed tomography (CT) and deep learning are feasible approaches for learning imaging-based prognostic representations. However, prognostic labels are difficult to obtain because survival endpoints require long-term follow-up; thus, labeled data for supervised training is limited, increasing the risk of overfitting. Vision-language pretraining offers an approach to mitigate this problem by leveraging large-scale unlabeled CT data; however, most existing methods are not specifically designed to learn prognosis-related features. We propose ProtoSurv, a prototype-guided learning framework for adapting large-scale pretrained CT representations for lung-cancer prognosis prediction under limited supervision. ProtoSurv first pretrains a CT-report vision-language model using 409,261 chest CT sequences from 104,783 patients. It then uses limited labeled prognosis data to construct class prototypes in the pretrained feature space. These prototypes guide pseudolabel assignment, confidence-based filtering, and feature calibration, allowing the selection and refinement of task-relevant unlabeled samples before downstream prognosis modeling. We evaluated ProtoSurv based on two lung-cancer prognosis tasks: progression-free survival prediction in 507 patients receiving targeted therapy and overall survival prediction in 420 patients receiving (chemo-)radiotherapy. ProtoSurv achieved area under the curve/concordance index values of 0.765/0.684 and 0.822/0.727 for the first and second datasets, respectively, outperforming the conventional clinical models and representative deep learning baselines. These results suggest that the prototype-guided adaptation can improve the use of large-scale unlabeled CT data for prognosis modeling when labeled survival data are limited.